ACE inhibition shows no benefit in the PEACE trial

A new systematic review by Carlberg and colleagues has revealed that atenolol, one of the most common β-blockers, might not be appropriate as a first-line treatment for hypertension. In a meta-analysis of four randomized, controlled trials comparing the drug with placebo (or no treatment) in 6,825 patients, there were no overall differences in the risk of… CONTINUE READING